Institutional Investors Amplify Stakes in ImmunityBio Following Strong Outlook
Published on 03/08/2026 at 04:27 | Redaktion boerse-global.de
Significant institutional buyers have substantially increased their holdings in biotechnology firm ImmunityBio, according to regulatory filings published this week. This surge in investment interest coincides with the company's recent announcement of a projected dramatic revenue increase for 2025, driven by its flagship product.
Financial Performance and Regulatory Milestones Provide Catalyst
The investment moves follow ImmunityBio's latest financial guidance. The company reported net product revenue for ANKTIVA reaching $113 million, which it states represents year-over-year growth of approximately 700%. For the fourth quarter alone, this figure stood at $38.29 million. The company's quarterly loss per share also showed improvement, coming in at $0.06, narrower than the consensus estimate of a $0.08 loss.
Concurrently, the company is advancing its global commercial strategy. Regulatory approvals have been secured in Saudi Arabia for applications in bladder cancer and metastatic non-small cell lung cancer. Furthermore, the European Medicines Agency has recommended a conditional marketing authorization, paving the way for a planned launch across 33 countries.
Major Funds Increase Their Positions
Recent documents filed with the U.S. Securities and Exchange Commission (SEC) reveal detailed buying activity by several major asset managers during the reporting period:
- Vanguard Group boosted its stake by 26.8%, adding approximately 5.83 million shares. This brings Vanguard's total holding to 27.65 million shares, valued at roughly $68 million.
- Rafferty Asset Management expanded its position by 79.2%, acquiring nearly 200,000 additional shares to hold a total of 452,458.
- Geode Capital Management also increased its investment, adding 1.48 million shares to reach an aggregate holding of 5.77 million shares.
ImmunityBio's stock closed at $8.67 on Friday. Over the past 52 weeks, its share price has traded between $1.83 and $12.43.
Should investors sell immediately? Or is it worth buying ImmunityBio?
Clinical Progress and Strategic Initiatives
Additional momentum stems from recent clinical updates. ImmunityBio announced the complete enrollment of 366 patients in its randomized QUILT 2.005 study for non-muscle invasive bladder cancer. A regulator-requested interim analysis at nine months demonstrated a complete response rate of 84% for the combination therapy, compared to 52% for standard therapy alone.
Based on this data, the company plans a new regulatory submission in the fourth quarter of 2026.
In response to global supply shortages for established bladder cancer treatments, ImmunityBio has activated an expanded access program for its recombinant therapies. By the end of February, 580 patients were enrolled across approximately 100 active study centers for this program.
Ad
ImmunityBio Stock: New Analysis - 8 March
Fresh ImmunityBio information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
